Acta Scientific Pharmaceutical Sciences (ISSN: 2581-883X)

Review Article Volume 4 Issue 8

Novel COVID-19 Pandemic Scenario: A Review of the Current Literature

Anilkumar V1*, Murali Krishna B2, Sangeeta Kumari L3 and Kalyani R2

1Assistant Professor, Department of Pharmaceutical Technology, GIET School of Pharmacy, Rajahmundry, East Godavari, Andhra Pradesh, India
2Assistant Professor, Department of Pharmaceutical Technology, Sri Venkateswara College of Pharmacy, Etcherla, Srikakulam, Andhra Pradesh, India
3Assistant Professor, Department of Pharmaceutical Analysis and Quality Assurance, Raghu College of Pharmacy, Dakamarri, Visakhapatnam, Andhra Pradesh, India

*Corresponding Author: Anilkumar V, Assistant Professor, Department of Pharmaceutical Technology, GIET School of Pharmacy, Rajahmundry, East Godavari, Andhra Pradesh, India.

Received: June 22, 2020; Published: July 09, 2020



The Pandemic which COVID-19 has made on the Globe needs no depiction. The disease caused by SARS-COV-2 presents flu-like symptoms which can be become serious in high-risk individuals. In this review article we provide an overview of the symptoms, treatment, diagnostic tools, drugs usages, vaccine trials options for Novel COVID-19. We carried out a systematic literature search using the main online databases like Google scholar, PUBMED, Medscape daily News by using keywords like COVID-19, corona virus. We included different publications from last six months data which focused clinical features and treatment. We found entry mechanism of virus into the body, Hand hygiene is key factor to prevent contamination, wear gloves in specified situations. The amin symptoms of COVID-19 are cough, fever, fatigue, slight dyspnea etc. RT-PCR, LAMP, ELISA is used as an analytical instrument utilizing Nasal swab, tracheal suction or bronchoalveolar lavage tests. The primary treatment being used to treat the infection are antibiotics, antiviral drugs like chloroquine. Therefore this review article main theme is focusing on many treatments have been proposed, self quarantine, isolation is the main medication that seems, by all accounts to be powerful in decreasing virus rate specifically designed randomized clinical trials are excepted to determine the most appropriate evidence-based treatment methodology more research work to be carried out to provide more reliable and valid effect to control and mange public emergency in both acute and chronic conditions of coronavirus.

Keywords: COVID-19; Pandemic; RT-PCR; LAMP; ELISA; Prevention; SARS-COV-2; Literature; Medscape; Google Scholar



  1. Muhammad Adnan Shkhana., et al. “COVID-19 infection: origin, transmission, and characteristics of human corona viruses”. Journal of Advanced Research 24 (2020): 91-98.
  2. WHO Novel corona virus situation dashboard. Geneva, Switzerland: WHO (2020).
  3. Wu D., et al. “The SARS-COV-2 outbreak: What we know”. International Journal of Infectious Diseases 94 (2020): 44-48.
  4. "2019 Novel corona virus (2019-nCoV)". Centres for Disease Control and Prevention (2020).
  5. Geller C., et al. "Human corona viruses: insights into environmental resistance and its influence on the development of new antiseptic strategies". Viruses11 (2012): 3044-3068.
  6. Luk HK., et al. “Molecular epidemiology, evolution and psychology of SARS coronavirus”. Infection, Genetics and evolution 71 (20119): 21-30.
  7. Coronavirus in viral (2019).
  8. Cascella M., et al. “Napoli RD: Features, evaluation and treatment coronavirus (COVID-19)”. Statpearls Publishing, Treasure Island, FL (2020).
  9. Maier H., et al. “Coronavirus: methods and protocols”. Coronavirus Method Protac (2015): 1-282.
  10. Li X., et al. “Molecular Immune Pathogenesis and Diagnosis of COVID-19”. Journal of Pharmaceutical Analysis 19 (2020): 1-7.
  11. KWOK YL., et al. “Face touching: a frequent habit that has implications for hand hygiene”. American Journal of Infection Control 43 (2015): 112-114.
  12. To KK., et al. “Consistent detection of 2019 novel corona virus in saliva”. Clinical Infectious Diseases (2020).
  13. Amber Father., et al. “Corona various disease (COVID-19). Implications for clinical”. Dental care JOE5. P584-595.
  14. Van Boheemen., et al. “Genomic characterization of newly discovered corona virus associated with acute respiratory distress syndrome in humans”. M Bio6 (2012): e00473-e512.
  15. VS Raj., et al. “Dipeptidyl peptidase 4 is a functional receptor for the emerging human corona virus-EMC”. Nature7440 (2013): 251-254.
  16. Bertram I., et al. “Cleavage and activation of the severe acute respiratory syndrome corona virus spike protein by human airway tryspin-like protease”. Journal of virology24 (2011): 13363-13372.
  17. X Xu., et al. “Evolution of the novel corona virus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission”. Science China Life Sciences3 (2020): 457-460.
  18. Shereen MA., et al. “COVID-19 Infection: origin, Transmission and characteristics of Human Coronavirus” 24 (2020): 91-98.
  19. Maier HJ., et al. “Coronavirus: methods and protocols, coronavirus method protective” (2015): 1-282.
  21. , et al. “A review of COVID-19 (coronavirus disease-2019) diagnosis, treatment and prevention”.
  22. Signal T. “A Review of coronavirus diseases-2019 (COVID-19)”. Indian Journal of Pediatric4 (2020): 281-286.
  24. , et al. “COVID-19: An overview”. WJPR 9 (2020): 1810-1827.
  25. Mile Green., et al. “What tests could potentially be used for the Screening, diagnosis and monitoring of COVID-19” (2020).
  26. Micheal J., et al. “Laboratory diagnosis of emerging human corona virus infections”.
  27. Maharshi Malakar. "Coronavirus- A review article”. Acts scientific Dental Sciences5 (2020): 10-12.
  28. BX Wang E.N Fish editors Global virus outbreaks: Interferon as 1st responder seminars in Immunology Elsevier (2019).
  29. M Wang., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel corona virus (2019-nCoV) in-vitro”. Cell Research 1-3 (2020).
  30. ML Holshue., et al. “First case of 20919 novel corona virus in the United States”. The New England Journal of Medicine (2020).
  31. VK Derebail., et al. “ANCA-associated Vassilitish refining therapy with plasma exchange and glucocorticoids”. The New England Journal of Medicine (2020).
  32. White NJ. et al. "Malaria". Lancet 9918 (2014): 723-735.
  33. Vincent MJ., et al. “Chloroquine is a potent inhibitor of SARS corona virus infection and spread”. Virology Journal 2 (2005): 69.
  34. Kapoor KM and Kapoor A. "Role of chloroquine and Hydroxy chloroquine in the treatment of COVID-19 Infection-A systematic literature Review". (2020).
  35. “Benefit over risk of using chloroquine and Hydroxy chloroquine in COVID-19 patients”. World Journal of Pharmaceutical Research 9.5 (2020): 772-777.
  36. Interferon therapy may speed recovery from COVID-19 Medscape (2020).
  37. Remedesvir shortness COVID-19 time to Recovery in published study-Medscape (2020).
  38. Yeming Wang., et al. “Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multi centre trail”. The Lancet10236 (2020): P1569-1578.
  39. Beigel J and Bray M. “Current and future antiviral therapy of severe seasonal and avian influenza”. Antiviral Research1 (2008): 91-102.
  40. Glenmark to commence new phase 3 clinical trail on combination of two antiviral drugs favipiravir and umifenovir in hospitalized patients of moderate COVID-19 in India. PR News.
  41. COVID-19 drug in India after DCGI approval COVID-19 drug in India after DCGI approval https://mumbaimirror. India (2020).
  42. Jiancheng Z., et al. “Current status of Potential therapeutic Candidates for the COVID-19 Crisis, Brain, Behavior, and Immunity”.
  43. Hung FT., et al. “A Review of SARS-COV-2 and the ongoing trials”. International Journal of Molecular Sciences 21 (2020): 2657.
  44. Hsieh HP and Hsu JT. “Strategies of development of antiviral agents directed against influenza virus replication”. Current Pharmaceutical Design 34 (2007): 3531-3542.
  45. Jonathan Grein., et al. “Original Article compassionate use of Remdesivir for patients with Severe COVID-19”. The New England Journal of Medicine 382 (2020): 2327-2336.
  46. Dayal D and Gupta S. “Connecting BCG vaccination and COVID-19: Additional Data”. Med Rxiv (2020).
  48. , et al. “CORONAVIRUS (COVID-19): Clinical features, diagnosis and treatment” 9 (2020).
  49. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395 (2020): 49740.
  50. W Guan., et al. “Clinical characteristics of Coronavirus Diseases 2019 in China”.
  51. Richman DD., et al. Clinical virology, 4th Washington: Asm Press (2016).
  52. Garner JS., et al. “CDC definitions of nosocomial infections, 1988”. American Journal of Infection Control 16 (1988): 128-140.


Citation: Anilkumar V., et al. “Novel COVID-19 Pandemic Scenario: A Review of the Current Literature".Acta Scientific Pharmaceutical Sciences 4.8 (2020): 03-11.


Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor1.197

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US